Log In
BCIQ
Print this Print this
 

CD3xCD123 DART molecule (MGD006)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody against CD3 and CD123 developed using Dual-Affinity Re-Targeting (DART) technology
Molecular Target CD3 ; Interleukin-3 (IL-3) receptor alpha (CD123)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,100.0M

$20.0M

$1,000.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/24/2012

$1,100.0M

$20.0M

$1,000.0M

Get a free BioCentury trial today